PIN29 Cost-Effectiveness of Nirsevimab Against Respiratory Syncytial VIRUS (RSV) Among US Infants Experiencing Their First RSV Season
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.588
https://www.valueinhealthjournal.com/article/S1098-3015(21)00805-6/fulltext
Title :
PIN29 Cost-Effectiveness of Nirsevimab Against Respiratory Syncytial VIRUS (RSV) Among US Infants Experiencing Their First RSV Season
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00805-6&doi=10.1016/j.jval.2021.04.588
First page :
Section Title :
Open access? :
No
Section Order :
10064